Detalhe da pesquisa
1.
In vivo efficacy & resistance prevention of cefiderocol in combination with ceftazidime/avibactam, ampicillin/sulbactam or meropenem using human-simulated regimens versus Acinetobacter baumannii.
J Antimicrob Chemother;
78(4): 983-990, 2023 04 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36775993
2.
Cefiderocol for the Treatment of Infections Due to Metallo-B-lactamase-Producing Pathogens in the CREDIBLE-CR and APEKS-NP Phase 3 Randomized Studies.
Clin Infect Dis;
75(6): 1081-1084, 2022 09 29.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35148378
3.
In Vitro Susceptibility of Gram-Negative Pathogens to Cefiderocol in Five Consecutive Annual Multinational SIDERO-WT Surveillance Studies, 2014 to 2019.
Antimicrob Agents Chemother;
66(2): e0199021, 2022 02 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34807757
4.
Efficacy of Cefiderocol in Experimental Stenotrophomonas maltophilia Pneumonia in Persistently Neutropenic Rabbits.
Antimicrob Agents Chemother;
66(10): e0061822, 2022 10 18.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36154614
5.
Iron serum levels and iron homeostasis parameters in patients with nosocomial pneumonia treated with cefiderocol: post hoc analysis of the APEKS-NP study.
Eur J Clin Microbiol Infect Dis;
41(3): 467-476, 2022 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35025025
6.
Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Analyses of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Patients with Pneumonia, Bloodstream Infection/Sepsis, or Complicated Urinary Tract Infection.
Antimicrob Agents Chemother;
65(3)2021 02 17.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33257454
7.
Intrapulmonary pharmacokinetic profile of cefiderocol in mechanically ventilated patients with pneumonia.
J Antimicrob Chemother;
76(11): 2902-2905, 2021 10 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34383901
8.
Evidence-Based Study Design for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia.
J Infect Dis;
219(10): 1536-1544, 2019 04 19.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30649434
9.
Pharmacokinetic and Pharmacodynamic Profiles of Cefiderocol, a Novel Siderophore Cephalosporin.
Clin Infect Dis;
69(Suppl 7): S552-S558, 2019 11 13.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31724042
10.
Pathogen-focused Clinical Development to Address Unmet Medical Need: Cefiderocol Targeting Carbapenem Resistance.
Clin Infect Dis;
69(Suppl 7): S559-S564, 2019 11 13.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31724048
11.
Efficacy of Humanized Cefiderocol Exposures over 72 Hours against a Diverse Group of Gram-Negative Isolates in the Neutropenic Murine Thigh Infection Model.
Antimicrob Agents Chemother;
63(2)2019 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30420477
12.
Population Pharmacokinetic Analysis of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Healthy Subjects, Subjects with Various Degrees of Renal Function, and Patients with Complicated Urinary Tract Infection or Acute Uncomplicated Pyelonephritis.
Antimicrob Agents Chemother;
62(2)2018 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29038272
13.
In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016.
Antimicrob Agents Chemother;
62(2)2018 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29158270
14.
Erratum for Karlowsky et al., "In Vitro Susceptibility of Gram-Negative Pathogens to Cefiderocol in Five Consecutive Annual Multinational SIDERO-WT Surveillance Studies, 2014 to 2019".
Antimicrob Agents Chemother;
67(6): e0042723, 2023 Jun 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37154749
15.
Progress in the Fight Against Multidrug-Resistant Bacteria 2005-2016: Modern Noninferiority Trial Designs Enable Antibiotic Development in Advance of Epidemic Bacterial Resistance.
Clin Infect Dis;
65(1): 141-146, 2017 Jul 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29017263
16.
Efficacy of Humanized Exposures of Cefiderocol (S-649266) against a Diverse Population of Gram-Negative Bacteria in a Murine Thigh Infection Model.
Antimicrob Agents Chemother;
61(11)2017 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28848004
17.
Pharmacokinetic/Pharmacodynamic Modeling and Simulation of Cefiderocol, a Parenteral Siderophore Cephalosporin, for Dose Adjustment Based on Renal Function.
Antimicrob Agents Chemother;
61(1)2017 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27795374
18.
Efficacy of Cefiderocol against Carbapenem-Resistant Gram-Negative Bacilli in Immunocompetent-Rat Respiratory Tract Infection Models Recreating Human Plasma Pharmacokinetics.
Antimicrob Agents Chemother;
61(9)2017 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28630178
19.
In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against a Recent Collection of Clinically Relevant Gram-Negative Bacilli from North America and Europe, Including Carbapenem-Nonsusceptible Isolates (SIDERO-WT-2014 Study).
Antimicrob Agents Chemother;
61(9)2017 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28630181
20.
US FDA's Assessment of the Benefit-risk of Cefiderocol for its Initial Complicated Urinary Tract Infection Indication.
Clin Infect Dis;
73(4): 751-752, 2021 08 16.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34398951